argenx is trading 11.12% down at $825.17 after announcing it would discontinue its Phase 3 UNITY study of efgartigimod in adults with moderate-to-severe Sjögren’s disease.
- Announced October 8, 2026, the decision followed an independent monitoring committee’s recommendation after an interim analysis found the trial was unlikely to meet its primary endpoint.
- The setback removes a potential Vyvgart growth opportunity in rheumatology. Reuters reported shares were on track for their biggest one-day fall in almost three years; broader market weakness may also add pressure.